Cambridge, MA-based Surface Oncology (OTC:SURF) is approaching its U.S. debut with the filing of an S-1.
The clinical-stage immuno-oncology firm develops next-generation cancer therapies that it says will perform better than first-gen offerings like checkpoint inhibitors by virtue of targeting the tumor microenvironment with multiple antibody generation platforms in parallel.
Lead candidate is SRF231 which targets a cancer cell surface protein called cluster of differentiation 47 (CD47). A Phase 1 study began last month with preliminary data expected in H1 2019. Next up is SRF373 which targets CD73. Collaboration partner Novartis (NYSE:NVS) filed an IND last month. A Phase 1 study should commence this year.
READ FULL ARTICLE HERE

